Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 1627 other investors.
Redeye returns with an updated take on the pick-and-shovel play Genovis following its partner Selecta Biosciences’ licensing deal with Astellas Pharma and the company’s Q4 2022 report. With reinforced confidence in the deal with Selecta, we have raised our base case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
The strong growth in the core business during the fourth quarter continues in the beginning of 2023
Today Selecta Biosciences announced the sublicensing of the Xork enzyme to Astellas Pharma for development with AT845, an investigational Astellas Gene Therapies' product, for the treatment of Pompe Disease.
Redeye returns with an updated take on the pick-and-shovel play Genovis following a site visit and change of lead analyst.
Genovis has signed a long-term licensing and supply agreement with a US based biotech company for the supply of SmartEnzymes[TM] to be used in the manufacturing of a clinical therapeutic agent. The new customer represents Genovis' second partner in the Bioprocess application area.
Genovis AB and evitria AG today signed a service agreement to offer evitria's customers fast LC-MS characterization of recombinant antibodies using Genovis proprietary enzyme technologies. evitria AG is a world leading service provider for recombinant antibody expression in CHO cells with headquarters in Zürich, Switzerland.
The Annual General Meeting adopted the following resolutions:
The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted.
The Board and the Chief Executive Officer were discharged from liability.
The Board shall consist until the next AGM of five ordinary members without deputies.
Re-election of Board members Torben Jørgensen, Mikael Lönn, Lotta Ljungqvist and Steve Jordan.
Magnus Gustafsson was elected new Board member.